The stem cell therapy developer, exploiting research from Digital Photonics and Nanoscience Laboratory, has set up a US subsidiary.

TreeFrog Therapeutics, a France-based stem cell therapy developer advancing research from Digital Photonics and Nanoscience Laboratory (LP2N), completed a $75m series B round yesterday led by Bpifrance’s Large Venture fund.
Investment firm Leonard Green & Partners and XAnge, the venture capital arm of private equity group Siparex, also took part in the round, as did pharmaceutical firm Bristol Myers Squibb.
Founded in 2018, TreeFrog Therapeutics has created a high-throughput cell encapsulation technology dubbed C-Stem that enables the mass…

Thierry Heles

Thierry Heles is the former editor-at-large of Global University Venturing and Global Corporate Venturing, and was the producer and host of the Beyond the Breakthrough podcast until December 2024.